

1 **Title:** Prevalence of Function-Limiting Late Effects in Hodgkin Lymphoma Survivors

2 **Authors:**

3 Nabela Enam\*, MD

4 Affiliation: Department of Physical Medicine & Rehabilitation, Rutgers New Jersey Medical School,

5 Newark, NJ, USA

6

7 Kathy Chou, DO

8 Affiliation: Department of Physical Medicine & Rehabilitation, Rutgers New Jersey Medical School,

9 Newark, NJ, USA

10

11 Michael D. Stubblefield, MD

12 Affiliation: Kessler Institute for Rehabilitation, West Orange, NJ, USA; Department of Physical Medicine

13 & Rehabilitation, Rutgers New Jersey Medical School, Newark, NJ, USA

14

15 **Presentation Acknowledgements:** None

16 **Financial Acknowledgements:** None

17 **Reprints:** Not available

18 **Conflicts of Interest:** None

19

20 **Correspondence:**

21 Nabela Enam

22 Mailing Address: 5765 Centre Avenue, Apt 426, Pittsburgh, PA 15206

23 Phone: 410-961-2280

24 E-mail: [enamn@upmc.edu](mailto:enamn@upmc.edu)

25

26 **Clinical Trial Registration Number:** N/A

27 **Abstract:**

28 **Objective:** To define the prevalence of neuromuscular, musculoskeletal, pain, visceral,  
29 oncologic and other late effects impacting function and quality of life in Hodgkin lymphoma  
30 (HL) survivors presenting to an outpatient cancer rehabilitation clinic.

31 **Design:** A retrospective cohort analysis.

32 **Setting:** Outpatient cancer rehabilitation clinic.

33 **Participants:** One hundred consecutive HL survivors.

34 **Interventions:** None.

35 **Main Outcome Measures:** The prevalence of neuromuscular, musculoskeletal, pain, visceral,  
36 oncologic and other late effects contributing to functional impairment and disability in HL  
37 survivors.

38 **Results:** Among the 100 HL survivors, 43% received chemotherapy, 94% radiation therapy, and  
39 38% a combination of chemotherapy and radiation for initial treatment. Nearly all HL survivors  
40 were diagnosed with myelopathy (83%), radiculo-plexopathy (93%), mononeuropathy (95%)  
41 and localized myopathy (93%). Musculoskeletal sequelae were extremely common and included  
42 dropped head syndrome (83%), cervicgia (79%), shoulder girdle dysfunction (73%), and  
43 dysphagia (42%). Visceral disorders were also common and included cardiovascular (70%),  
44 pulmonary (44%), endocrine (63%), gastrointestinal (29%), and genitourinary (11%)  
45 dysfunction. Lymphedema affected 21% of survivors and 30% had a history of a secondary  
46 malignancy. Pain (71%), fatigue (45%), and dyspnea (43%) were major function-limiting  
47 impairments. Nearly all (95%) of survivors were referred to at least one therapy discipline  
48 including physical therapy, occupational therapy, speech and language pathology and/or  
49 lymphedema therapy.

50 **Conclusion:** Neuromuscular, musculoskeletal, pain, visceral, oncologic and other late effects  
51 are extremely common in HL survivors seeking physiatric evaluation. Multiple function-limiting  
52 disorders can co-exist in HL survivors with the potential to severely compromise function and  
53 quality of life. Safe and effective rehabilitation may depend on the physiatrist's ability to  
54 identify, evaluate and manage the multitude of complex and often interrelated functional late  
55 effects seen in HL survivors.

56

57 **Key Words:**

58 Hodgkin lymphoma, late effects, survivorship, quality of life, rehabilitation

59

60 **List of Abbreviations:**

61 ADL- activities of daily living

62 CMT- combined modality therapy

63 DHS- dropped head syndrome

64 HL- Hodgkin lymphoma

65 OT- occupational therapy

66 PT- physical therapy

67 RT- radiation therapy

68 SGD- shoulder girdle dysfunction

69 SLP- speech and language pathology therapy

70 QOL- quality of life

71 **Introduction**

72 Hodgkin lymphoma (HL), formerly Hodgkin’s disease, is named for Thomas Hodgkin the  
73 physician who, in 1832, first described the clinical history and postmortem findings of massive  
74 enlargement of the lymph nodes and spleens.<sup>1</sup> The first reports that x-rays could shrink the  
75 enlarged lymph nodes associated with HL emerged in the early 1900’s,<sup>2</sup> and evidence that  
76 localized HL could be cured by radiation therapy (RT) was presented by Vera Peters in 1950.<sup>3</sup> It  
77 was not until 1970 that HL became the first advanced malignancy of a major organ system in  
78 adults to be cured by chemotherapy.<sup>4,5</sup> Combined modality therapy (CMT), meaning combining  
79 chemotherapy with RT for HL, was slow to develop, and up until the 1990’s patients were often  
80 treated with radiation as a single modality. Contemporary treatment of HL has evolved but still  
81 generally utilizes CMT with an overall 5-year survival rate of 86%.<sup>6</sup> Most HL survivors treated  
82 today will enjoy an equivalent life expectancy to those of healthy age-matched individuals.  
83 HL treatment is notorious for causing visceral, oncologic, musculoskeletal, and neuromuscular  
84 late effects.<sup>7</sup> RT is particularly toxic and can damage any tissue or system within the radiation  
85 fields used to treat HL. Dysfunction is seen in the nerves and muscles encompassed by the  
86 radiation field including the spinal cord, nerve roots, plexus, peripheral nerves, and muscles. This  
87 phenomenon, termed “myelo-radiculo-plexo-neuro-myopathy,” can develop years or decades  
88 following completion of RT and progress indefinitely.<sup>8</sup> Visceral late effects include those of the  
89 cardiovascular, pulmonary, gastrointestinal, urogenital, and endocrine systems. Secondary  
90 malignancies are also often seen.<sup>9</sup>  
91 Considerable effort has focused on the visceral and oncologic late effects of HL survivors with  
92 studies largely occurring in oncology and survivorship settings. Resulting guidelines are  
93 generally intended for oncologists, medical survivorship specialists, and primary care physicians.

94 There is little data concerning the issues faced by HL survivors in the rehabilitation medicine  
95 setting.

96 The goal of this retrospective, cohort analysis is to identify the prevalence of neuromuscular,  
97 musculoskeletal, visceral, oncologic and other late effects contributing to functional impairment  
98 and disability in HL survivors seeking cancer rehabilitation medicine services. Comprehensively  
99 elucidating the multitude of complex and interrelated issues faced by HL survivors will educate  
100 rehabilitation physicians and improve the longitudinal care of this often misunderstood and  
101 underserved cohort of patients. Additionally, highlighting the potential impact of visceral  
102 complications on function and quality of life (QOL) in HL survivors will highlight the need for  
103 rehabilitation physicians to expand their role with respect to these disorders.

104

## 105 **Methods**

106 This study was approved by the Institutional Review Board at the Kessler Foundation. Data for  
107 100 sequential patients previously diagnosed and treated for late effects of HL was available and  
108 included in the study. Alternative primary cancer diagnoses were excluded. Each patient was  
109 seen at least once at a cancer rehabilitation outpatient clinic in New Jersey between March 2015  
110 and March 2020. A cancer rehabilitation physiatrist evaluated the patients and chart review was  
111 completed by all authors. Data collection included patient demographics, stage of HL at  
112 diagnosis, treatment (chemotherapy and/or RT), treatment-related late effects (neuromuscular,  
113 musculoskeletal, visceral, oncologic), and rehabilitation therapy type prescribed. Treatment with  
114 chemotherapy was documented as either present or absent. Radiation fields were classified as:  
115 mantle, mediastinal, subtotal, periaortic, or total.

116

117 *Neuromuscular and Musculoskeletal Complications*

118 Neuromuscular and musculoskeletal late effects were recorded as documented in the medical  
119 record. Clinical evaluation, including detailed history and comprehensive physical examination,  
120 was the primary basis for diagnosis of all neuromuscular and musculoskeletal disorders. When  
121 the spinal cord, nerve roots, plexus, peripheral nerves and muscles within the radiation field were  
122 affected together, it was termed “myelo-radiculo-plexo-neuro-myopathy” (this appeared on page  
123 3).<sup>8</sup> Neuromuscular complications were identified as myelopathy, radiculopathy, plexopathy,  
124 mononeuropathy or myopathy based upon the clinical criteria defined below and as previously  
125 described.<sup>10</sup>

- 126 • Myelopathy, usually subacute in presentation, was suspected in patients demonstrating  
127 neurologic deficits consistent with spinal cord involvement. This included loss of bowel  
128 or bladder function (including detrusor sphincter dyssynergia), sexual dysfunction, and  
129 upper motor signs (eg. hyperreflexia, clonus and spasticity).
- 130 • Radiculopathy and plexopathy, resulting from nerve root or plexus compression,  
131 respectively, were suspected in patients demonstrating sensory abnormalities in the  
132 appropriate dermatomal distribution, weakness in muscles innervated by the affected  
133 structure, and diminished deep tendon reflexes in an anatomically congruent distribution.  
134 As these conditions could not be reliably differentiated from each other based on clinical  
135 grounds when co-existent, patients exhibiting these signs and symptoms were usually  
136 grouped together as a single entity (radiculo-plexopathy) unless clinical evidence  
137 indicated one structure (i.e. plexus) was more severely affected.

138

- 139       • Mononeuropathy was suspected when patients presented with symptoms of numbness,  
140       tingling, burning, pain, weakness, and/or atrophy in the distribution of a peripheral nerve.
- 141       • Myopathy was suspected in the setting of primary muscle disease with or without nerve  
142       involvement and characterized by weakness with muscle wasting and atrophy often  
143       accompanied by pain. This was differentiated from atrophy due to denervation based on  
144       the clinical pattern of exaggerated muscle atrophy within the radiation field compared to  
145       muscle atrophy in the distribution of affected structures such as the nerve root, plexus,  
146       and peripheral nerves.

147   Other primarily neurologic complications included sexual dysfunction, cognitive impairment  
148   (e.g. memory deficits) and gait dysfunction.

149   Although primary bone, joint, and soft tissue dysfunction underlie the musculoskeletal disorders  
150   encountered in HL survivors, neuromuscular damage is likely the major contributing factor.

151   While some disorders, such as dropped head syndrome (DHS) and dysphagia are usually  
152   considered neuromuscular in etiology, the effects of radiation on soft tissue and bone (vertebrae,  
153   hyoid) are likely important in HL survivors and support their classification as at least partially  
154   musculoskeletal for the purposes of this study. Musculoskeletal syndromes resulting from  
155   neuromuscular damage in HL survivors include DHS, cervicalgia, shoulder girdle dysfunction  
156   (SGD), dysphagia, and trismus with clinical criteria for diagnosis defined below.

- 157       • DHS was defined by weakness in head elevation that ranged from mild (end-of-day  
158       cervical fatigue and pain) to severe (minimal or no neck extension, muscle bulk or  
159       strength). This diagnosis was based on self-reported history and/or physical examination  
160       wherein the patient demonstrated difficulty elevating the head with absent or feeble  
161       cervical paraspinal muscle contraction on palpation.

- 162       • Cervicalgia was defined in patients reporting neck pain with a history of radiation  
163       exposure with or without evidence of DHS.
- 164       • SGD was defined as limited shoulder range of motion, weakness in active movement,  
165       and/or pain. Rotator cuff tendonitis, adhesive capsulitis, osteoarthritis, and other specific  
166       shoulder pathology diagnoses were consolidated into SGD.
- 167       • Dysphagia was defined by patient complaints of difficulty swallowing, choking episodes,  
168       or diagnosed from formal swallow evaluation.
- 169       • Trismus was defined as contraction of the muscles and other tissues of mastication  
170       leading to restricted jaw opening.

171

#### 172 *Visceral and Oncologic Complications*

173 Visceral and oncologic complications seen in HL survivors included cardiac, pulmonary,  
174 endocrine, gastrointestinal, genitourinary dysfunction, lymphedema, and secondary  
175 malignancies. These complications were recorded based upon outside physician consultation and  
176 documentation, patient's self-reporting, or suspicion and investigation by the physiatrist.

- 177       • Cardiovascular dysfunction included documented history of valvular dysfunction,  
178       arrhythmias, coronary artery disease, pericardial dysfunction, congestive heart failure,  
179       myocardial dysfunction, carotid stenosis and baroreceptor failure. Baroreceptor failure  
180       was characterized by fluctuations in blood pressure and heart rate resulting from damage  
181       to the receptors (carotid baroreceptors) in the neck.
- 182       • Pulmonary dysfunction included documented pulmonary fibrosis based on restrictive  
183       lung disease pattern confirmed on pulmonary function tests.

184



- 185       • Endocrine dysfunction included documented history of hypothyroidism or  
186       osteoporosis/osteopenia.
- 187       • Gastrointestinal dysfunction included documented history of dyspepsia (i.e. ulcers and  
188       reflux) or bowel dysmotility.
- 189       • Genitourinary dysfunction included documented history of detrusor sphincter  
190       dyssynergia, urinary retention, or incontinence.
- 191       • Lymphedema was included when documented in the patient’s history or observed on  
192       physiatric evaluation.
- 193       • Secondary malignancy included documented history of any cancer following initial  
194       diagnosis of HL deemed likely secondary to HL treatment.

195

#### 196 *Functional Impairments*

197 The presence of symptoms that interfered with QOL and independence in activities of daily  
198 living (ADLs) were documented. This included patient reports of pain, fatigue, and dyspnea.

199

#### 200 *Therapy Referrals*

201 The type of therapy prescribed including physical therapy (PT), occupational therapy (OT),  
202 speech language pathology therapy (SLP), and lymphedema therapy was recorded. Patients  
203 receiving multiple therapy disciplines were noted.

204

### 205 **Results**

206 Charts of 100 HL survivors were reviewed (Table 1). Of these, 63 (63%) were female. Twenty-  
207 two (22%) were diagnosed with HL before age 19, 51% were diagnosed between 20-29 years of

208 age, 19% were diagnosed between 30-39 years of age, and 8% were diagnosed over the age of  
209 40. Known cancer staging at the time of initial HL diagnosis showed 17 (17%) patients with  
210 stage I, 40 (40%) with stage II, 19 (19%) with stage III, and 5 (5%) with stage IV (Table 1).  
211 Twenty-four survivors had nodular sclerosing HL, 1 had mixed cellularity type, 1 had both, and  
212 74 had an unknown cellular type (data not shown).  
213 Among all survivors, 43 (43%) received chemotherapy and 94 (94%) received radiation (Table  
214 1). Thirty-eight (38%) received combined chemotherapy and radiation as their initial HL  
215 treatment (data not shown). The majority of survivors received radiation involving the thoracic  
216 region, 44 (44%) received mantle, 2 (2%) isolated mediastinal, 6 (6%) subtotal, 2 (2%)  
217 periaortic, and 35 (35%) total nodal radiation (Table 1). The known radiation total doses ranged  
218 from 1400 cGy to 4920 cGy.  
219 The majority of HL survivors demonstrated signs and symptoms consistent with myelo-radiculo-  
220 plexo-neuro-myopathy. Eighty-three (83%) demonstrated myelopathy, 93% radiculo-plexopathy,  
221 95% mononeuropathy, and 93% myopathy. Of the neurologic complications, mononeuropathy  
222 was most common, manifesting in 95 (95%) of survivors. All subjects demonstrated at least one  
223 concurrent neurologic complication. Other neurologic complications identified in HL survivors  
224 included 8% with sexual dysfunction, 11% with neurocognitive impairments, and 39% with gait  
225 dysfunction (Table 2).  
226 Musculoskeletal clinical syndromes resulting from neuromuscular dysfunction were common in  
227 HL survivors including 83 (83%) with DHS, 73 (73%) with SGD, 79 (79%) with cervicalgia, 42  
228 (42%) with dysphagia and 3 (3%) with trismus (Table 2).  
229 The cardiovascular system was the second most commonly affected system with 70 (70%)  
230 experiencing at least one cardiovascular disorder and 15 (15%) two, 7 (7%) three and 2 (2%)

231 four cardiovascular impairments. Of these, 43 (43%) had valvular abnormalities, 27 (27%)  
232 cardiac arrhythmias, 13 (13%) coronary artery disease, 7 (7%) pericardial dysfunction, 6 (6%)  
233 congestive heart failure, 4 (4%) myocardial dysfunction, 4 (4%) baroreceptor failure, and 3 (3%)  
234 carotid stenosis (Table 2).

235 Pulmonary fibrosis was diagnosed in 44 (44%) patients, and 21 (21%) experienced lymphedema  
236 (Table 2). Fifty-nine (59%) survivors were diagnosed with hypothyroidism and 17 (17%) with  
237 osteoporosis or osteopenia. A total of 29 (29%) patients experienced gastrointestinal dysfunction  
238 including 12 (12%) with dysmotility and 17 (17%) with dyspepsia. Eleven (11%) survivors  
239 reported genitourinary abnormalities (Table 2).

240 HL recurrence occurred in 22 (22%) patients and 30 (30%) patients developed secondary  
241 malignancies. Forty-three (43%) patients described dyspnea, 45 (45%) experienced fatigue, and  
242 71 (71%) reported pain (Table 2).

243 Therapy was prescribed to the vast majority (95%) of survivors (Table 3). Twenty-eight (28%)  
244 required two disciplines, 7 (7%) three disciplines, and 1 (1%) four disciplines. Ninety-four (94%)  
245 survivors received PT, 15 (15%) received OT, 21 (21%) SLP, and 12 (12%) received  
246 lymphedema therapy.

247

## 248 **Discussion**

249 HL is a highly curable disease owing to advances in treatment. The cost of cure, however, is  
250 extremely high for the survivors who develop severe function-limiting late effects (Figure 1a, 1b,  
251 1c). These impairments encompass neuromuscular, musculoskeletal, pain, visceral, and  
252 oncologic abnormalities. Unchallenged by intervention, function and QOL will decline  
253 indefinitely, a fact that has led radiation late effects to be labeled with the moniker “the gift that

254 keeps on giving”. Although more work clarifying the value of specific rehabilitation  
255 interventions is needed, the fundamental role for psychiatry in identifying and managing the  
256 functional late effects common to HL survivors is clear.

257 In our chart review of 100 HL survivors referred to a cancer rehabilitation specialist, all had one  
258 or more function limiting issues as would be expected based on their seeking psychiatric  
259 evaluation and treatment. Most patients had multiple impairments. This is consistent with other  
260 studies that have identified the systemic late effects likely to be seen in this population.<sup>11,12</sup> Prior  
261 investigations have not, however, focused on the neuromuscular, musculoskeletal, and functional  
262 complications that are likely to affect QOL and ADL in HL survivors.

263 Neuromuscular deficits can affect all levels of the neural axis in HL survivors. Nearly all (95%)  
264 survivors exhibited at least one neuromuscular disorder and most (83%) were found to have  
265 multiple levels affected based on clinical evaluation. Neuromuscular impairments in this  
266 population are usually attributed to radiation-induced damage of nerves and muscles within or  
267 traversing the radiation field, a phenomenon termed “myelo-radiculo-plexo-neuro-myopathy”.<sup>8,10</sup>

268 Disorders such as radiculopathy from degenerative causes and peripheral neuropathy from  
269 diabetes or neurotoxic chemotherapy exposure are also potential factors in some patients. The  
270 musculoskeletal syndromes observed included DHS (83%), cervicalgia (79%), SGD (73%), and  
271 dysphagia (42%) which is consistent with radiation-induced impairments observed in other  
272 cohorts.<sup>13</sup> It is the authors opinion that the musculoskeletal syndromes described in this study  
273 result in large part from, and are secondary to, neuromuscular dysfunction which should be  
274 considered the primary disorder.

275 Cardiovascular complications were the second most prevalent following neuromuscular  
276 disorders, affecting 70% of survivors. Previous studies have demonstrated that radiation in HL

277 survivors is associated with autonomic dysfunction<sup>14</sup>, valvular dysfunction<sup>15</sup>, and that cardiac  
278 mortality is a leading cause of death.<sup>16</sup> A significant number of survivors had pulmonary (44%)  
279 and endocrine (63%) disorders as well. Twenty-two percent had a previously documented  
280 recurrence of HL and 30% developed a secondary malignancy. The high prevalence of visceral  
281 impairment in this study should serve to emphasize the tremendous complexity and need for  
282 close medical management of this population.

283 The importance of screening in HL survivors is increasingly recognized. Surveillance guidelines  
284 for late effects have been published. Particular attention has been given to cardiovascular and  
285 secondary malignancies which confer significant mortality in this population.<sup>11,17</sup> The National  
286 Comprehensive Cancer Network (NCCN) as well as many societies have established  
287 recommended follow-up and surveillance algorithms for HL survivors. These guidelines include  
288 regular bloodwork, thyroid evaluation, cardiovascular risk and symptom assessment, and regular  
289 cancer screening.<sup>9,18,19</sup>

290 There are multiple treatments available that may improve function and optimize QOL in HL  
291 survivors. For physiatrists, this includes controlling pain, prescribing appropriate therapeutic  
292 interventions (i.e., PT, OT, SLP), and monitoring for changes in clinical status. Because of the  
293 tremendous medical complexity associated with HL survivors, coordination of care with other  
294 medical disciplines such as oncology, cardiology, and endocrinology is critically important for  
295 optimal rehabilitation outcomes. Physiatrists should seek to understand the full scope and scale  
296 of medical issues affecting HL survivors as they are instrumental to identifying issues early and  
297 coordinating care appropriately.

298

299 *Study Limitations*

300 There are several limitations to our study. The high percentage of patients demonstrating signs  
301 and symptoms of myelo-radiculo-plexo-neuro-myopathy and resulting neuromuscular  
302 complications likely represents a highly biased population of patients seeking specialized  
303 physiatric care. This is probably not representative of all HL survivors. The neurologic diagnoses  
304 were generally based on clinical evaluation alone and may be erroneous in some cases. No  
305 attempt was made to correlate treatment with impairments or impairments with functional  
306 outcome. Future studies should seek to make these correlations and shed light on which  
307 interventions are most likely to be effective at restoring function and QOL to HL survivors.

308

### 309 **Conclusion**

310 HL survivors are well known to develop neuromuscular, musculoskeletal, pain, visceral, and  
311 oncologic late effects as a result of treatment. These impairments can have major implications  
312 for function and QOL. These disorders are not only extremely common, but are likely to occur  
313 together in patients seeking cancer rehabilitation services. Physiatric evaluation and management  
314 can be instrumental in maximizing function and QOL in this cohort of cancer survivors. To  
315 achieve this potential, it is imperative that physiatrists treating these patients understand the full  
316 scope and scale of these disorders to ensure they support safe and effective rehabilitation.

317

318

319

320

321

322 **References**

- 323 1. Hodgkin. On some Morbid Appearances of the Absorbent Glands and Spleen. *Med Chir Trans.*  
324 1832;17:68-114.
- 325 2. Pusey W. Cases of sarcoma and of Hodgkin's disease treated by exposures to X-rays - a  
326 preliminary report. *JAMA.* 1902;38(3):166-169.
- 327 3. Peters MV. A study of survivals in Hodgkin's disease treated radiologically. *Am J Roentgenol.*  
328 1950;63(3):299-311.
- 329 4. Devita VT, Jr., Serpick AA, Carbone PP. Combination chemotherapy in the treatment of  
330 advanced Hodgkin's disease. *Ann Intern Med.* 1970;73(6):881-895.
- 331 5. Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin  
332 lymphoma: a 50-year perspective. *J Clin Oncol.* 2014;32(3):163-168.
- 333 6. Cancer Stat Facts: Hodgkin Lymphoma. National Cancer Institute.  
334 <https://seer.cancer.gov/statfacts/html/hodg.html>.
- 335 7. Ng AK, van Leeuwen FE. Hodgkin lymphoma: Late effects of treatment and guidelines for  
336 surveillance. *Seminars in hematology.* 2016;53(3):209-215.
- 337 8. Stubblefield MD. Radiation fibrosis syndrome: neuromuscular and musculoskeletal  
338 complications in cancer survivors. *PM R.* 2011;3(11):1041-1054.
- 339 9. Darrington DL, Vose JM. Appropriate surveillance for late complications in patients in remission  
340 from Hodgkin lymphoma. *Curr Hematol Malig Rep.* 2012;7(3):200-207.
- 341 10. Stubblefield MD. Neuromuscular complications of radiation therapy. *Muscle Nerve.*  
342 2017;56(6):1031-1040.
- 343 11. Ng AK. Current survivorship recommendations for patients with Hodgkin lymphoma: focus on  
344 late effects. *Blood.* 2014;124(23):3373-3379.
- 345 12. Kilickap S, Barista I, Ulger S, et al. Long-term complications in Hodgkin's lymphoma survivors.  
346 *Tumori.* 2012;98(5):601-606.

- 347 13. Ghosh PS, Milone M. Clinical and laboratory findings of 21 patients with radiation-induced  
348 myopathy. *J Neurol Neurosurg Psychiatry*. 2015;86(2):152-158.
- 349 14. Groarke JD, Tanguturi VK, Hainer J, et al. Abnormal exercise response in long-term survivors of  
350 hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction  
351 and impact on outcomes. *J Am Coll Cardiol*. 2015;65(6):573-583.
- 352 15. Bijl JM, Roos MM, van Leeuwen-Segarceanu EM, et al. Assessment of Valvular Disorders in  
353 Survivors of Hodgkin's Lymphoma Treated by Mediastinal Radiotherapy +/- Chemotherapy. *Am*  
354 *J Cardiol*. 2016;117(4):691-696.
- 355 16. Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. *J*  
356 *Am Coll Cardiol*. 2013;61(23):2319-2328.
- 357 17. Thompson CA, Mauck K, Havyer R, Bhagra A, Kalsi H, Hayes SN. Care of the adult Hodgkin  
358 lymphoma survivor. *Am J Med*. 2011;124(12):1106-1112.
- 359 18. Engert A, Dreyling M, Group EGW. Hodgkin's lymphoma: ESMO clinical recommendations for  
360 diagnosis, treatment and follow-up. *Ann Oncol*. 2008;19 Suppl 2:ii65-66.
- 361 19. MD Anderson Cancer Center. Survivorship- Hodgkin's Lymphoma. 2019.

362

363



364 **Figure Legends:**

365 Figure 1.

366 A typical Hodgkin lymphoma survivor. This woman in her 60's has a history of stage II nodular  
367 sclerosing Hodgkin lymphoma that was diagnosed in her 30's. She was treated with subtotal  
368 radiation resulting in multiple neuromuscular (myelopathy, radiculopathy, plexopathy,  
369 mononeuropathy, myopathy), musculoskeletal (dropped head syndrome, cervicalgia, shoulder  
370 dysfunction), functional (pain, fatigue, dyspnea) and visceral (cardiovascular, pulmonary,  
371 endocrine) late effects.

372

373

Table 1. Hodgkin Lymphoma survivor demographics, lymphoma history and treatment

<b>Variable</b>	<b>N (%)</b>
<b>Sex</b>	
Men	37 (37%)
Women	63 (63%)
<b>Age at Diagnosis</b>	
< 19yrs	22 (22%)
20-29yrs	51 (51%)
30-39yrs	19 (19%)
40-49yrs	5 (5%)
> 50yrs	3 (3%)
<b>Hodgkin's Stage at Diagnosis</b>	
Stage 1A, 1B, I unspecified	12 (12%), 3 (3%), 2 (2%)
Stage IIA, IIB, II unspecified	24 (24%), 12 (12%), 4 (4%)
Stage IIIA, IIIB, III unspecified	10 (10%), 5 (5%), 4 (4%)
Stage IVA, IVB, IV unspecified	1 (1%), 2 (2%), 2 (2%)
Unknown stage	19 (19%)
<b>Received chemotherapy</b>	43 (43%)
No chemotherapy	55 (55%)
Unknown chemotherapy history	2 (2%)
<b>Radiation treatment</b>	94 (94%)
Mantle	44 (44%)
Mediastinal	2 (2%)
Subtotal	6 (6%)
Periaortic	2 (2%)
Total	35 (35%)
Unknown	5 (5%)
No radiation treatment	6 (6%)

Table 2. Diagnoses identified in Hodgkin Lymphoma survivors

<b>Diagnosis</b>	<b>N (%)</b>
<b>Neuromuscular</b>	
Myelopathy	83 (83%)
Radiculo-plexopathy	93 (93%)
Mononeuropathy	95 (95%)
Myopathy	93 (93%)
<b>Other Neurologic</b>	
Sexual Dysfunction	8 (8%)
Cognitive Impairment	11 (11%)
Gait Dysfunction	39 (39%)
<b>Musculoskeletal</b>	
Dropped head syndrome	83 (83%)
Cervicalgia	79 (79%)
Shoulder girdle dysfunction	73 (73%)
Dysphagia	42 (42%)
Trismus	3 (3%)
<b>Visceral</b>	
Cardiovascular dysfunction	70 (70%)
2 cardiovascular impairments	15 (15%)
3 cardiovascular impairments	7 (7%)
4 cardiovascular impairments	2 (2%)
Valvular	43 (43%)
Arrhythmia	27 (27%)
Coronary artery disease	13 (13%)
Pericardial dysfunction	7 (7%)
Congestive heart failure	6 (6%)
Myocardial dysfunction	4 (4%)
Baroreceptor Failure	4 (4%)
Carotid stenosis	3 (3%)
Pulmonary fibrosis	44 (44%)
Endocrine dysfunction	63 (63%)
Hypothyroidism	59 (59%)
Osteopenia/osteoporosis	17 (17%)
Gastrointestinal dysfunction	29 (29%)
Dyspepsia	17 (17%)
Bowel dysmotility	12 (12%)
Genitourinary dysfunction	11 (11%)
Lymphedema	21 (21%)
<b>Oncologic</b>	52 (52%)
Secondary malignancy	30 (30%)
Cancer Recurrence	22 (22%)
<b>Functional impairment</b>	
Pain	71 (71%)
Fatigue	45 (45%)
Dyspnea	43 (43%)

Table 3. Therapy referrals for Hodgkin Lymphoma survivors

<b>Therapy Referrals</b>	<b>N (%)</b>
Any	95 (95%)
2 disciplines	28 (28%)
3 disciplines	7 (7%)
4 disciplines	1 (1%)
Physical therapy	94 (94%)
Speech language pathology	21 (21%)
Occupational therapy	15 (15%)
Lymphedema therapy	12 (12%)

medRxiv preprint doi: <https://doi.org/10.1101/2020.10.02.20202408>; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: <https://doi.org/10.1101/2020.10.02.20202408>; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



